RELATED PARTY TRANSACTIONS |
12 Months Ended | |
|---|---|---|
Dec. 31, 2016 | ||
| Related Party Transactions [Abstract] | ||
| Related Party Transactions Disclosure [Text Block] |
15. RELATED PARTY TRANSACTIONS
The Company’s former Chief Scientific Officer and principal founder of Cellectar, Inc. who resigned July 2016 and continues to be a shareholder of the Company, is a faculty member at the University of Wisconsin-Madison (“UW”). During 2016 the Company incurred approximately $225,000 in expenses from UW for costs associated with clinical trial agreements. During 2015 the Company incurred approximately $178,000 in expenses from UW which was also related to the costs associated with clinical trial agreements. The Company had accrued liabilities to UW of approximately $64,000 and $40,000 as of December 31, 2016 and 2015, respectively.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|